BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18627526)

  • 1. A novel transport and delivery mechanism underpins the effectiveness of prolyl-m-sarcolysyl-p-fluorophenylalanine (PSF) in a human melanoma xenograft nude-mouse model.
    Dierickx KM; Morandini R; Nguyen TH; Salès F; Kauffmann JM; Ghanem GE
    Pigment Cell Melanoma Res; 2008 Aug; 21(4):439-50. PubMed ID: 18627526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity and DNA cross-linking induced by peptide conjugated m-L-sarcolysin in human melanoma cells.
    Hansson J; Lewensohn R; Ringborg U
    Anticancer Res; 1991; 11(5):1725-30. PubMed ID: 1768043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
    Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL
    Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
    Rice JR; Gerberich JL; Nowotnik DP; Howell SB
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice.
    Lu JL; Wang JC; Zhao SX; Liu XY; Zhao H; Zhang X; Zhou SF; Zhang Q
    Eur J Pharm Biopharm; 2008 Aug; 69(3):899-907. PubMed ID: 18434109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas.
    Hwang TL; Lee WR; Hua SC; Fang JY
    J Dermatol Sci; 2007 Apr; 46(1):11-20. PubMed ID: 17267180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy.
    Zhao H; Peng P; Longley C; Zhang Y; Borowski V; Mehlig M; Reddy P; Xia J; Borchard G; Lipman J; Benimetskaya L; Stein CA
    J Control Release; 2007 Jun; 119(2):143-52. PubMed ID: 17397960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Establishment of EL4 tumor-bearing mouse models and investigation on immunological mechanisms of anti-tumor effect of melphalan].
    Li ML; Li CG; Shu XH; Jia YJ; Qin ZH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Mar; 22(2):235-8. PubMed ID: 16507262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models.
    Rapp M; Maurizis JC; Papon J; Labarre P; Wu TD; Croisy A; Guerquin-Kern JL; Madelmont JC; Mounetou E
    J Pharmacol Exp Ther; 2008 Jul; 326(1):171-7. PubMed ID: 18411412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
    Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I
    Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
    Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
    Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
    Abi-Habib RJ; Singh R; Leppla SH; Greene JJ; Ding Y; Berghuis B; Duesbery NS; Frankel AE
    Clin Cancer Res; 2006 Dec; 12(24):7437-43. PubMed ID: 17189417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship between sensitivity of tumor cells to chemotherapeutic agent in vivo and in vitro: experiment with mouse lymphoma cells].
    Li CG; Li ML; Shu XH; Jia YJ; Liu YJ; Li M
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(22):1576-8. PubMed ID: 17785116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor action of bovine seminal ribonuclease. Cytostatic effect on human melanoma and mouse seminoma.
    Poucková P; Soucek J; Jelínek J; Zadinová M; Hlousková D; Polívková J; Navrátil L; Cinátl J; Matousek J
    Neoplasma; 1998; 45(1):30-4. PubMed ID: 9604999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo.
    Meier-Davis SR; Dines K; Arjmand FM; Hamlin R; Huang B; Wen J; Christianson C; Shudo J; Nagata T
    Cutan Ocul Toxicol; 2012 Dec; 31(4):312-7. PubMed ID: 22515841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours.
    Schwab RE; Froidevaux S; Paku S; Tejeda M; Szende B; Pap A; Beglinger C; Eberle AN; Kéri G
    Anticancer Res; 2001; 21(1A):71-5. PubMed ID: 11299792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.
    Gullbo J; Dhar S; Luthman K; Ehrsson H; Lewensohn R; Nygren P; Larsson R
    Anticancer Drugs; 2003 Sep; 14(8):617-24. PubMed ID: 14501383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoemulsion preparations of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model.
    Tagne JB; Kakumanu S; Nicolosi RJ
    Mol Pharm; 2008; 5(6):1055-63. PubMed ID: 19434855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.